Freedom performs better with ticlopidine
This article was originally published in Clinica
Executive Summary
Global Therapeutics' Freedom stent performs poorly in calcified lesions, research carried out in the EU has shown. Dr Bernard Chevallier of the Centre Cardiologique du Nord, France, presented data from the first 530 patients treated there and in Belgium up to the beginning of March. Ten percent of patients received more than one stent - bringing the total number of implants to 633. Recoil occurred in 9.3% and technical success was 96.3%, Dr Chevallier told delegates at the ACC meeting. The 21 failures were mostly in calcified lesions.